Current Science

Open Access Open Access  Restricted Access Subscription Access

Vaccine and Drug Trials in the COVID-19 Pandemic: Lessons For India


Affiliations
1 Ashoka University, Sonepat 131 029, India
2 Katoch is in the NASI-ICMR Chair on Public Health Research at Rajasthan University of Health Sciences, Jaipur 302 004, India
 

The Coronavirus pandemic has caught most countries off guard, unprepared to handle a fast-spreading viral infection with a high rate of fatality and absence of any prophylactics and preventive agents. It has made it clear that a strong scientific base with access to novel technology platforms, trained scientific manpower and flexible regulatory systems are required to fight such infections and prevent future infections to go out of control. Developing the scientific and technology base could have a ripple effect in fighting several other incurable diseases, such as many forms of cancer and genetic disorders.
User
Notifications
Font Size

  • Holmes, E., http://virological.org/t/initialgenome-release-of-novel-coronavirus/ 319

  • https://www.statnews.com/2020/03/19/ an-updated-guide-to-the-coronavirusdrugsand-vaccines-in-development/

  • https://www.fiercepharma.com/vaccines/ china-s-cansino-pushes-coronavirusvaccineinto-clinical-testing-as-modernadoses1st

  • https://economictimes.indiatimes.com/news/ international/world-news/oxford-universitybegins-enrolling-over-500-volunteersforcoronavirus-vaccine-trial/articleshow/ 74864754.cms?from=mdr

  • Saroja, Ch., Lakshmi, P. and Bhaskaran, S., Int. J. Pharm. Investig., 2011, 1, 64– 74.

  • Dubensky Jr, T. W., Liu, M. A. and Ulmer, J. B., Mol. Med., 2000, 6, 723–732.

  • https://www.who.int/blueprint/prioritydiseases/ key-action/novel-coronaviruslandscapencov.pdf?ua=1

  • Richardson, J. S., Dekker, J. D., Croyle, M. A. and Kobinger, G. P., Hum. Vaccin., 2010, 6, 439–449.

  • Acosta, P. L., Caballero, M. T. and Polack, F. P., Clin. Vaccine Immunol., 2015, 23, 189–195.

  • Rauch, S., Jasny, E., Schmidt, K. E. and Petsch, B., Front Immunol., 2018, 9, 1963.

  • Neuzil, K. M., Clin. Vaccine Immunol., 2016, 23, 186–188.

  • Machicado, J. D., Bhagya-Rao, B., Davogustto, G. and McKelvy, B. J., Clin. Vaccine Immunol., 2013, 20, 1485–1486.

  • Thor, S. W., Hilt, D. A., Kissinger, J. C., Paterson, A. H. and Jackwood, M. W., Viruses, 2011, 3, 1777–1799.

  • Shi, M. et al., Nature, 2018, 556, 197– 202.

  • https://deepmind.com/research/opensource/ computational-predictions-of-proteinstructures-associated-with-COVID-19 16. http://diosvax.com/covidresponse 17. Nair, N. P. et al., BMJ Open, 2019, 9, e024840.


Abstract Views: 368

PDF Views: 127




  • Vaccine and Drug Trials in the COVID-19 Pandemic: Lessons For India

Abstract Views: 368  |  PDF Views: 127

Authors

Alok Bhattacharya
Ashoka University, Sonepat 131 029, India
Sudha Bhattacharya
Ashoka University, Sonepat 131 029, India
Viswa Mohan Katoch
Katoch is in the NASI-ICMR Chair on Public Health Research at Rajasthan University of Health Sciences, Jaipur 302 004, India

Abstract


The Coronavirus pandemic has caught most countries off guard, unprepared to handle a fast-spreading viral infection with a high rate of fatality and absence of any prophylactics and preventive agents. It has made it clear that a strong scientific base with access to novel technology platforms, trained scientific manpower and flexible regulatory systems are required to fight such infections and prevent future infections to go out of control. Developing the scientific and technology base could have a ripple effect in fighting several other incurable diseases, such as many forms of cancer and genetic disorders.

References





DOI: https://doi.org/10.18520/cs%2Fv119%2Fi2%2F171-172